Form 8-K - Current report:
SEC Accession No. 0001558370-25-003987
Filing Date
2025-03-28
Accepted
2025-03-28 16:05:36
Documents
15
Period of Report
2025-03-25
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sngx-20250325x8k.htm   iXBRL 8-K 38022
2 EX-3.1 sngx-20250325xex3d1.htm EX-3.1 167083
  Complete submission text file 0001558370-25-003987.txt   364387

Data Files

Seq Description Document Type Size
3 EX-101.SCH sngx-20250325.xsd EX-101.SCH 4027
4 EX-101.DEF sngx-20250325_def.xml EX-101.DEF 3492
5 EX-101.LAB sngx-20250325_lab.xml EX-101.LAB 17908
6 EX-101.PRE sngx-20250325_pre.xml EX-101.PRE 10507
18 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20250325x8k_htm.xml XML 5030
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14778 | Film No.: 25785935
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)